Avaliação dos níveis solúveis de VEGFR-1 e PlGF em mulheres com câncer de mama
Nenhuma Miniatura disponível
Data
2024-06-05
Autores
Silva, Kamylla Ramos da [UNIFESP]
Orientadores
Torres, Leuridan Cavalcante [UNIFESP]
Tipo
Dissertação de mestrado
Título da Revista
ISSN da Revista
Título de Volume
Resumo
Introdução: O câncer de mama (CM) é a doença neoplásica que mais acomente mulheres no mundo e é fundamental a determinação do estadiamento clínico, realizado a partir das características do tumor, nódulo e metástase. Os subtipos de CM são classificados como luminal A (LA), luminal B (LB), HER2 e triplo negativo (TN). A angiogênese é determinante para a progressão tumoral devido ao potencial alvo-terapêutico dos fatores de crescimento endotelial vascular, tais como o Soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) e o Placental Growth Factor (PlGF). Objetivo: Avaliar os níveis séricos de VEGFR-1 e PIGF em mulheres com câncer de mama a fim de estabelecer um painel prognóstico. Métodos: Foram incluídas 71 mulheres com câncer de mama com idade entre 18 anos a 60 anos. As pacientes apresentavam os seguintes subtipos tumorais: Luminais A/B, HER2+ e Triplo Negativo. As análises de sVEGFR-1 e PlGF foram realizadas por EnzymeLinked Immunosorbent Assay (ELISA). Resultados: Os níveis de sVEGFR-1 foram elevados nas pacientes com câncer de mama com estádio IV comparados grupo com estádio III (P=0,0402). Os níveis de PlGF foram elevados no grupo T4 comparado ao grupo T1-T2 (P=0,0133). Foram observados níveis elevados de PlGF nas pacientes CM que foram a óbito (P=0,0149) comparado aos que sobreviveram. Foram observados níveis elevados PlGF nas pacientes com CM subtipo Luminal A/B e estádio III-IV comparado I-II (P=0,0450), e nos tumores T3-T4 (P=0,0168) apresentaram níveis elevados de PlGF comparado ao grupo T1-T2. Foram observados níveis baixos sVEGFR-1 e PlGF nas pacientes CM subtipo HER2+ e estádio III-IV comparado I-II (P=0,0137 e P=0,0148, respectivamente). Nas pacientes com câncer de mama triplo negativo, não foram observadas diferenças significativas nos níveis de sVEGFR-1 e PlGF entre os grupos, de acordo com as variáveis estadiamento, tamanho tumoral e status linfonodal. Foi observada uma correlação positiva entre os níveis de sVEGFR-1 e PlGF nas pacientes com câncer de mama (r=0.421; P<0,001). Conclusão: A alterações encontradas nos níveis sVEGFR-1 e PIGF parecem estar associados ao pior prognóstico no câncer de mama HER2+ e Luminal A/B.
Introduction: Breast cancer (BC) is the neoplastic disease that most affects women in the world and it is essential to determine clinical staging, based on the characteristics of the tumor, nodule, and metastasis. BC subtypes are classified as luminal A (LA), luminal B (LB), HER2, and triple negative (TN). Angiogenesis is a determinant of tumor progression due to the target-therapeutic potential of vascular endothelial growth factors, such as Soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) and Placental Growth Factor (PlGF). Objective: To evaluate serum levels of VEGFR-1 and PIGF in women with breast cancer in order to establish a prognostic panel. Methods: 71 women with breast cancer aged between 18 years to 60 years old were included. The patients had the following tumor subtypes: Luminal A/B, HER2+ and Triple Negative. sVEGFR-1 and PlGF analyzes were performed by Enzyme-Linked Immunosorbent Assay (ELISA). Results: sVEGFR-1 levels were elevated in patients with stage IV breast cancer compared to the stage III group (P=0.0402). PlGF levels were elevated in the T4 group compared to the T1-T2 group (P=0.0133). High levels of PlGF were observed in BC patients who died (P=0.0149) compared to those who survived. Elevated PlGF levels were observed in patients with Luminal A/B and stage III-IV compared to I-II (P=0.0450), and T3-T4 (P=0.0168) tumors showed elevated levels of PlGF compared to the T1-T2. Low sVEGFR-1 and PlGF levels were observed in subtype HER2+ and stage IIIIV compared to I-II patients (P=0.0137 and P=0.0148, respectively). In patients with triple-negative breast cancer, no significant differences were observed in the levels of sVEGFR-1 and PlGF between the groups, according to the variables staging, tumor size and lymph node status. A positive correlation was observed between sVEGFR-1 and PlGF levels in breast cancer patients (r=0.421; P<0.001). Conclusion: The changes found in sVEGFR-1 and PIGF levels appear to be associated with a worse prognosis in HER2+ and Luminal A/B breast cancer
Introduction: Breast cancer (BC) is the neoplastic disease that most affects women in the world and it is essential to determine clinical staging, based on the characteristics of the tumor, nodule, and metastasis. BC subtypes are classified as luminal A (LA), luminal B (LB), HER2, and triple negative (TN). Angiogenesis is a determinant of tumor progression due to the target-therapeutic potential of vascular endothelial growth factors, such as Soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) and Placental Growth Factor (PlGF). Objective: To evaluate serum levels of VEGFR-1 and PIGF in women with breast cancer in order to establish a prognostic panel. Methods: 71 women with breast cancer aged between 18 years to 60 years old were included. The patients had the following tumor subtypes: Luminal A/B, HER2+ and Triple Negative. sVEGFR-1 and PlGF analyzes were performed by Enzyme-Linked Immunosorbent Assay (ELISA). Results: sVEGFR-1 levels were elevated in patients with stage IV breast cancer compared to the stage III group (P=0.0402). PlGF levels were elevated in the T4 group compared to the T1-T2 group (P=0.0133). High levels of PlGF were observed in BC patients who died (P=0.0149) compared to those who survived. Elevated PlGF levels were observed in patients with Luminal A/B and stage III-IV compared to I-II (P=0.0450), and T3-T4 (P=0.0168) tumors showed elevated levels of PlGF compared to the T1-T2. Low sVEGFR-1 and PlGF levels were observed in subtype HER2+ and stage IIIIV compared to I-II patients (P=0.0137 and P=0.0148, respectively). In patients with triple-negative breast cancer, no significant differences were observed in the levels of sVEGFR-1 and PlGF between the groups, according to the variables staging, tumor size and lymph node status. A positive correlation was observed between sVEGFR-1 and PlGF levels in breast cancer patients (r=0.421; P<0.001). Conclusion: The changes found in sVEGFR-1 and PIGF levels appear to be associated with a worse prognosis in HER2+ and Luminal A/B breast cancer
Descrição
Citação
SILVA, Kamylla Ramos da. Avaliação dos níveis solúveis de VEGFR-1 e PlGF em mulheres com câncer de mama. 2024. 81 f. Dissertação (Mestrado em Medicina Translacional) - Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, 2024.